C-telopeptides of type I collagen in postmenopausal women: An experience in a Tunisian Clinical Laboratory

##plugins.themes.academic_pro.article.main##

Kahena Bouzid
Afef Bahlous
Eya Kalaï
Hayet Fellah
Hela Sahli
Slaheddine Sellami
Jaouida Abdelmoula

Abstract

Aim: The purpose of study was to evaluate the interest of Ctelopeptides of type I collagen (CTX) in the diagnosis of osteoporosis in postmenopausal women and to define its cut-off value.
Methods: A transverse descriptive study enrolled postmenopausal women: 139 osteoporotic (G1) and 39 non osteoporotic (G2). The 2 groups were defined by bone density measurement. The following markers were measured: serum alkaline phosphatase (ALP), bone alkaline phosphatase (bone ALP), serum C-terminal telopeptide of type I collagen (CTX). Statistical analyses were performed using SPSS 10.5. The corresponding estimation of sensitivity and specificity of CTX have been presented as ‘receiver Operating Curve’ (ROC).
Results: There was no difference in the measurement of ALP and bone ALP in the 2 groups but CTX was statistically higher in G1 compared to G2 (p <0.001). The percentage of osteoporotic women (G1) with CTX values > 0.500 ng/ml was higher than that of non osteoporotic women (G2). We have established a ROC curve to find the cut-off value of CTX that enables the distinction between osteoporotic women with high level of bone remodelling, and non osteoporotic women. The cut-off value of CTX 0.55 pg/ml was the best; it associated best sensitivity and specificity.
Conclusion : The total increase and significance for CTX was greater in the group of osteoporotic women and appeared therefore to be a good bone turnover marker in the diagnosis of osteoporosis in comparison with ALP and bone ALP. The cut-off value of CTX 0.55 pg/ml may improve the sensitivity and specificity of prediction of future fractures.

Keywords:

Osteoporosis, bone markers, diagnosis

##plugins.themes.academic_pro.article.details##

References

  1. Ebeling P.R, Akesson K. Role of biochemical markers in the management of osteoporosis. Best Pract Res Clin Rheumatol 2001;15:385-400.
  2. Vasikaran SD. Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci 2008;45:221-58.
  3. Garnero P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.Mol Diagn Ther 2008; 12:157-70.
  4. Bhattacharyya S, Siegel ER, Achenbach SJ, Khosla S, Suva LJ. Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women. J Bone Miner Res 2008; 23:1106-17.